Ashish M. Kamat, MD, MBBS

@PGrivasMDPhD @HutchPresident @fredhutch @uwurology @DanLinMD @rarengan @VenurVyshak @mshadman @spsutkaMD @montypal @siadaneshmand @OncoAlert Congratulations all around!!

Agree with @HutchPresident Am thrilled to see stellar colleague/collaborator Dr. John Gore taking over this leadership role in Division of Surgical Oncology @fredhutch @uwurology @DanLinMD @rarengan @VenurVyshak @mshadman @spsutkaMD @montypal @siadaneshmand @UroDocAsh @OncoAlert

Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al Read the full article: buff.ly/AcADjoA We thank the authors for trusting EUO to publish your work @robertocontieri @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @UroDocAsh @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

@fredhutch Congratulations John!

We’re proud to announce the launch of Fred Hutch’s new Division of Surgical Oncology, a major step forward in advancing surgical innovation, translational science and multidisciplinary cancer care. Dr. John Gore has been named the division’s inaugural Division Director and SVP.

The International Bladder Cancer Group Travel Award to support outstanding fellows and early-career academic faculty committed to advancing the field of bladder cancer is now offered annually to provide emerging leaders the opportunity to participate in the IBCG Annual Retreat. Details at link: ibcg.info/ibcg-2025-trav… #BladderCancer #IBCG26

JSUO and IBCG collaborate on a global standard for TURBT surgical checklists. Rikiya Taoka, MD & @urouro_AS join @UroDocAsh @UTMDAnderson to discuss the JSUO partnership with IBCG and the standardized TURBT surgical checklist initiative. #WatchNow on UroToday > bit.ly/4rPO7fO

Huge congrats @UroDocAsh @IBCG_BladderCA on this major milestone! Your tremendous vision and leadership has shaped the way we think about intermediate risk bladder cancer and glad to see it embraced by the @NCCN @AndreaNecchi @pjhensley11 @UrogerliMD @SpiessPhilippe @BladderCancerUS @neerajaiims @PGrivasMDPhD @montypal

Congratulations @UroDocAsh @IBCG_BladderCA on this major accomplishment!

So exciting that this is now in the NCCN guidelines! No doubt that this will better stratify IR NMIBC patients for clinical trials. Grateful to @UroDocAsh and the @IBCG_BladderCA team for the opportunity to lead this work pubmed.ncbi.nlm.nih.gov/35718695/

@Aiims1742 @TomVargheseJr @aaas @nyulangone @Perlmutter_CC @RonDePinho Congratulations!

I am honored to be named an @aaas Fellow from @nyulangone @Perlmutter_CC Congratulations to all 2025 #AAASFellow inductees. Thank you @RonDePinho for the nomination. nyu.edu/about/news-pub…

@shilpaonc @IBCG_BladderCA @NCCN @AndreaNecchi @pjhensley11 @UrogerliMD @SpiessPhilippe Thanks Shilpa. Truly a team effort that you are a part of! Guided by principle that no patient should receive more treatment than they need, or less than they deserve.

@LauraBukavinaMD @NCCN @IBCG_BladderCA Thanks Laura. Truly a team effort guided by principle that no patient should receive more treatment than they need, or less than they deserve.

Absolutely amazing to see this added to the @NCCN framework 👏Kudos to @UroDocAsh for his tireless efforts& @IBCG_BladderCA for the many years spent building and validating evidence in the highly heterogeneous space of intermediate risk #bladdercancer

@niklas_kluemper @OncoAlert Well said.

Important trial tackling the right question first: can we safely preserve the bladder after cCR with EVP? But 9 cycles of EVP is associated with significant cumulative toxicity —especially neuropathy. In EV302 EPAR data, the KM curves show a clear exposure–toxicity relationship, with higher ADC exposure driving earlier and more frequent ≥G2 neuropathy. And G2 is already life-changing: difficulty buttoning shirts, typing, gait instability, chronic pain—this isn’t “mild.” We’ve learned before: In B15, 3 cycles neoadj EVP achieved similar pCR rates as 4 cycles in 905 → more is not always better. Effect of adjuvant EV not tested properly (VOLGA will be informative in this regard!) Maybe even fewer cycles can be sufficient. Response adapted dosing? (Imaging, ctDNA and/ or utDNA Dynamics)?) So yes—answering “bladder preservation safe?” first is the right strategy which will increasingly asked by the patients in real-world. But: ➡️ EV dose reduction & discontinuation must be proactive ➡️ Early signs of neuropathy should trigger action, not delayed adjustments ➡️ Cumulative exposure matters more than cycle count alone “EVP first, ask later” should not come at the cost of irreversible toxicity in a curative setting where surgery also cures many patients @UroDocAsh @tompowles1 @Uromigos @urotoday @Markuseckstein3 @OncoAlert @weoncologists @DrChoueiri @PGrivasMDPhD @AndreaNecchi @shilpaonc

Pleased to share that the 2026 @NCCN Bladder Cancer Guidelines now incorporate the @IBCG_BladderCa risk stratification framework for intermediate-risk NMIBC. A milestone reflecting more than a decade of collaborative work by colleagues worldwide einpresswire.com/article/901009… @UrogerliMD @drtanws @shilpaonc @pjhensley11 @mouwlab @AndreaNecchi @LAUrology_NL @AmirHorowitz @karima_oualla @PGrivasMDPhD @paolo_gontero @pcvblack @MaxKates @SpiessPhilippe @RobertoContieri @KKBree @LauraBukavinaMD @MRoupret @joanfundi @UroToday @BladderCancerUS @WorldBladderCan

Great initiative by the European Urology team! A smart way to stay current with the latest across EU journals. @EurUrolOpen @EurUrolOncol @EurUrolOncol @EUplatinum @Uroweb

Great points. B15 establishes the potency of EVP but we have to be careful not to conflate maximum systemic efficacy with total local clearance - they’re not the same thing, and the 55.8% pCR rate, impressive as it is, didn’t eliminate the need for the adjuvant tail to drive EFS and OS. If a patient achieves cCR after 3-4 cycles, pushing to 9 without a surgical safety net is a significant gamble on the durability of that systemic response. We know pCR plateaus - beyond a threshold we’re trading efficacy for toxicity - and cCR ≠ pCR regardless. 9 cycles as the defining threshold feels like a blunt instrument for a question that requires a scalpel (at least for now!)

Great points. B15 establishes the potency of EVP but we have to be careful not to conflate maximum systemic efficacy with total local clearance - they’re not the same thing, and the 55.8% pCR rate, impressive as it is, didn’t eliminate the need for the adjuvant tail to drive EFS and OS. If a patient achieves cCR after 3-4 cycles, pushing to 9 without a surgical safety net is a significant gamble on the durability of that systemic response. We know pCR plateaus - beyond a threshold we’re trading efficacy for toxicity - and cCR ≠ pCR regardless. 9 cycles as the defining threshold feels like a blunt instrument for a question that requires a scalpel (at least for now!)

Thanks Laura . My feeling is that the relationship between response in the primary tumour and metastatic sites varies between pateints. It will depend on the extent of MRD and the size of primary tumor. The biology/heterogeneity will also have an important role. 4 cycles will probably be too few for some, while 9 will be too much for others. Using pCR or cCR to define duration of therapy maybe counterproductive (like using IMDC to pick ipi/nivo treatment in RCC). utDNA and ctDNA together maybe be better at this. Designing studies with utDNA and ctDNA is hard as it takes a while to get initial results, but it’s a useful exploratory endpoint. I think we should do these studies too. EV209 asks is we can get the same results as in B15 if we do exactly the same thing except we don’t do surgery in some. It’s an interesting time as things change and I might not be right about this (e.g utDNA) @MattGalsky @shilpaonc @UroDocAsh @MichvdHeijden

A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’ #GUtrendingTopics @OncoAlert

It was a pleasure to host Meri-Margaret Deoudes, CEO of @BladderCancerUS (BCAN), for a conversation about the New Faces of Bladder Cancer - a landmark survey of 1,100 patients across 49 US states, released at #GU26 Link to 📽️on @UroToday here: urotoday.com/video-lectures… #BladderCancer #PatientAdvocacy @IBCG_BladderCA @PGrivasMDPhD @shilpaonc @apolo_andrea @SimaPorten

Really enjoyed this session with colleagues ⁦@UroDocAsh⁩ @BradMcG04 @mattgalsky ⁦@sonpavde led by ⁦@PGrivasMDPhD⁩ What’s Next in Bladder Cancer Treatment? - oncologynexus.com oncologynexus.com/video/whats-ne…

Kindness matters. That’s it. That’s the tweet.